Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to investigate the diagnostic and prognostic value of surfactant protein D, Krebs von den Lungen (KL-6), and Chitinase-3-like protein 1 (YKL-40) in the initial investigation of patients hospitalized with suspected pneumonia. This to improve the diagnosis of pneumonia, contribute to a more rapid and accurate antibiotic treatment, and assess disease severity to predict short-term and long-term mortality in community-acquired pneumonia patients.
Community-acquired pneumonia (CAP) is one of the most common infection diseases in the emergency department (ED). Diagnosis of pneumonia is challenging as symptoms are often weak and nonspecific and the current methods for focal and etiological diagnosis have low sensitivity and specificity and often deliver results after the antibiotic treatment decision has been made.
The abundant and restricted expression of surfactant protein D (SP-D) within the lung makes this protein a specific marker for lung disease. Krebs von den Lungen-6 (KL-6) is expressed in the lung and is a diagnostic and prognostic marker of interstitial lung disease. The inflammatory glycoprotein Chitinase-3-like protein 1 commonly known as YKL-40 is associated with severity of interstitial lung disease. The value of these lung injury markers for diagnosing pneumonia needs further investigation.
The investigators hypothesize that surfactant protein D, Krebs von den Lungen (KL-6), and Chitinase-3-like protein 1 (YKL-40) have an impact on diagnosing, prognosis, and treatment of patients with verified CAP.
The objectives of the study are:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Suspected CAP | All patients admitted to the emergency department with suspected community-acquired pneumonia (CAP) assessed by the receiving physician |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biomarkers for pneumonia | Diagnostic Test | Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of surfactant protein D, Krebs von den Lungen (KL-6), and YKL-40. Laboratory staff will be blinded to participant diagnosis and outcome. None of the biomarkers will be available to the treating physician.
|
| Measure | Description | Time Frame |
|---|---|---|
| Verified and non-verified community acquired pneumonia (CAP) | The decision of whether patients admitted with suspicion of CAP actually has a final diagnosis of CAP is based on a combination of all findings during admission. The verification of diagnosis requires human handling, interpretation and judgment. Therefore, in this study, an expert panel will define the reference standard for the diagnosis CAP. The expert panel consists of two independent consultants from the emergency department with significant experience in emergency medicine and acute infections. They will individually determine whether or not the patient admitted suspected with CAP actually had this diagnosis. The final diagnosis will be based on all available relevant information from the patient medical record including HR-CT of lungs. A standardized template will be used. Disagreement will be discussed until a consensus is reached. | 2 months after patient discharge |
| Measure | Description | Time Frame |
|---|---|---|
| Intensive care unit treatment | transfer to ICU during current admission (binary outcome) | within 60 days from admission to the emergency department |
| Length of stay | days spent in hospital during current admission |
| Measure | Description | Time Frame |
|---|---|---|
| Bacteriuria | Binary outcome defined by microbiologist on urine culture analysis | urine collected within 4 hours of arrival to emergency department |
| Diagnostic capabilities of Ultra low-dose computer thermography for pneumonia |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Acutely admitted patients with suspected Acute pyelonephritis (APN) from three emergency departments (EDs) in the Region of Southern Denmark (Hospital Sønderjylland, Hospital Lillebælt, Odense University Hospital)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christian Backer Mogensen | Esbjerg Hospital - University Hospital of Southern Denmark | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital of Southern Jutland | Aabenraa | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22554854 | Background | Ishikawa N, Hattori N, Yokoyama A, Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012 Mar;50(1):3-13. doi: 10.1016/j.resinv.2012.02.001. Epub 2012 Mar 8. | |
| 29473039 | Background | Sorensen GL. Surfactant Protein D in Respiratory and Non-Respiratory Diseases. Front Med (Lausanne). 2018 Feb 8;5:18. doi: 10.3389/fmed.2018.00018. eCollection 2018. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000098968 | Community-Acquired Pneumonia |
| D011014 | Pneumonia |
| D055370 | Lung Injury |
| D004630 | Emergencies |
| ID | Term |
|---|---|
| D017714 | Community-Acquired Infections |
| D007239 | Infections |
| D012141 | Respiratory Tract Infections |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| within 60 days from current admission to the emergency department |
| the number of participants who died within 30 days | binary - 30-days mortality | within 30 days from arrival day |
| The number of participants who died within 90 days | binary - 90-days mortality | within 90 days from arrival day |
| Readmission | binary | within 30 days from day of discharge |
| In-hospital mortality | binary | within 60 days from admission to the emergency department |
True positive, true negative, false positive and false negative for ultra low-dose computer thermography for pneumonia.
| Within 24 hours from hospital admission |
| Diagnostic capabilities of lung ultrasound for pneumonia | True positive, true negative, false positive and false negative for lunge ultrasound for pneumonia. | Within 24 hours from hospital admission |
| Diagnostic capabilities of chest x-ray for pneumonia | True positive, true negative, false positive and false negative for chest x-ray for pneumonia | Within 24 hours from hospital admission |
| Level of infection markers | Concentration of serum procalcitonin, CRP and suPAR | blood collected with 4 hours of arrival to emergency department |
| CURB-65 severity score | Confusion of new onset, Blood Urea nitrogen greater than 7 mmol/L (19 mg/dL), respiratory rate of 30 breaths per minute or greater, blood pressure less than 90 mmHg systolic or diastolic blood pressure 60 mmHg or less and age 65 or older. The score stratify patients to groups 1 (mild pneumonia), 2 (moderate pneumonia) and 3-5 (severe pneumonia). | within 4 hours from admission |
| Pneumonia severity index (PSI) | Risk classes to predict the severity of pneumonia. Scores are given based on demographics, comorbidity, clinical measurements and physical Exam Findings (<70 = Risk Class II, 71-90 = Risk Class III, 91-130 = Risk Class IV, >130 = Risk Class V) | within 4 hours from admission |
| Microbial agents | Microbial agents (bacteria and viruses) identified in standard culture, PCR and multiplex PCR. Sputum or tracheal secretion samples are collected within 1 hour from patient admission. | results within 7 days from sputum sample collection |
| 20347285 | Background | Furuhashi K, Suda T, Nakamura Y, Inui N, Hashimoto D, Miwa S, Hayakawa H, Kusagaya H, Nakano Y, Nakamura H, Chida K. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med. 2010 Aug;104(8):1204-10. doi: 10.1016/j.rmed.2010.02.026. Epub 2010 Mar 27. |
| D008171 | Lung Diseases |
| D013898 | Thoracic Injuries |
| D014947 | Wounds and Injuries |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |